This study describes the identification of a new class of biomarkers of cancer response to therapies based on protein modification by Ubiquitin and SUMO and provides the tools to analyze them in Acute Myeloid Leukemia patient samples.
Introduction
Ubiquitin family proteins (collectively called UbL hereafter) are peptidic post-translational modifiers (Streich & Lima, 2014) . The best-characterized ones are Ubiquitin and SUMO-1 to -3. SUMO-1 is 50% identical with SUMO-2 and -3, which are 97% identical. UbL are covalently and reversibly conjugated to the lateral chain of lysines from thousands of proteins.
Their conjugation involves dedicated enzymatic cascades comprising E1 UbL-activating enzymes (2 for Ubiquitin, 1 for SUMO), E2 UbL-conjugating enzymes (46 for Ubiquitin, 1 for SUMO) and several E3 factors (~700 for Ubiquitin, ~15 for SUMO) (Streich & Lima, 2014) . Ubiquitin can be conjugated to itself via the formation of isopeptide bonds between its C-terminal glycine and certain of its own lysines (K6, K11, K27, K29, K33, K48, K63) (Yau & Rape, 2016) . SUMO-2 and SUMO-3 can also form chains via SUMOylation of a specific N-terminal lysine, which is absent in SUMO-1 (Tatham et al, 2001) .
Due to the diversity of their target proteins, UbL control a large range of cellular functions.
As most other post-translational modifiers, they can either hide or create interaction surfaces on the conjugated protein. The consequences of ubiquitylation also largely depend on the type of chains, K48-linked ubiquitin chains being mostly known to constitute a protein degradation signal recognized by the 26S proteasome (Chau et al, 1989; Glickman & Ciechanover, 2002; Ciechanover, 2017) whilst other types of chains, notably K63-and K11-linked chains, have been involved in protein-protein interactions, signaling, inflammatory response, DNA repair and ribosomal function (Haakonsen & Rape, 2019; Kwon & Ciechanover, 2017) . SUMO is conjugated to more the 6000, mostly nuclear, proteins. In particular, many proteins involved in gene expression (transcription factors, transcription machinery, co-regulators, histones) are regulated by their SUMOylation (Neyret-Kahn et al, 2013; Cossec et al, 2018; Rosonina et al, 2017; Tempé et al, 2014; Chymkowitch et al, 2015) . SUMOylation also plays key roles in DNA damage repair through the modification of many proteins involved in this process (Garvin & Morris, 2017) .
Ubiquitin-like modifiers are critical players in the regulation of numerous cellular pathways and are involved in most, if not all, biological processes. As such dysregulation of the various enzymes involved in UbL conjugation are found in cancers and are involved in both tumorigenesis and cancer response to therapies (Mansour, 2018) . This includes, among others, E3 ubiquitin ligases such as MDM2 (Carr & Jones, 2016) , IAP (Mohamed et al, 2017) or F-box protein-containing SCF complexes (Uddin et al, 2016) .
Overexpression/downregulation of SUMOylation enzymes has also been reported in many cancers (Seeler & Dejean, 2017) , including various hematomalignancies (Boulanger et al, 2019) . For instance, the SUMO E2 was shown to be overexpressed in hepatocellular carcinomas, where it participates to their resistance to doxorubicin (Fang et al, 2017) or in multiple myeloma, where it is a marker of bad prognosis (Driscoll et al, 2010) . In addition, many components of the SUMO pathway, including the E1, E2 and various PIAS E3 proteins were shown to be highly expressed in B-cell lymphomas overexpressing c-Myc. This results in overall higher SUMO conjugation in these cells and makes them vulnerable to the inhibition of SUMOylation (Hoellein et al, 2014) . Finally, we have recently shown that it plays an important role in the response of Acute Myeloid Leukemia (AML) to standard chemotherapies and in the resistance of non-promyelocytic AML to differentiation therapies using retinoic acid (Baik et al, 2018) . UbLs, UbLconjugating/deconjugating enzymes and UbL-conjugated substrates therefore constitute a potential new class of biomarkers to predict cancer response to therapies.
AML represent a very heterogeneous group of cancers affecting the myeloid lineage. They arise through the acquisition of oncogenic mutations or rearrangements by hematopoietic stem or -progenitor cells, which, instead of differentiating into normal leukocytes, proliferate and invade the bone marrow. The historical FAB (French American British) classification of AML was mostly based on the differentiation stage of the leukemic cells. It has now been replaced by the WHO classification, which is based on the number and nature of their genetic abnormalities (Döhner et al, 2017) . It defines groups with favorable, intermediate or adverse prognosis (Estey, 2012; Dombret & Gardin, 2016) . Except for the Acute Promyelocytic subtype (~10% of AML), which is the only one that can be effectively treated by a differentiation therapy (retinoic acid and arsenic trioxide) (Ng & Chng, 2017) , patients diagnosed for all other AML subtypes are generally subjected to a chemotherapeutic treatment that has not significantly changed for the past 40 years (Dombret & Gardin, 2016) .
This standard therapy starts with a remission induction treatment combining two genotoxics, one anthracycline (daunorubicin-DNR or idarubicin-IDA) and cytarabine (Ara-C) (3+7 regimen), which is followed by a consolidation treatment using only Ara-C. However, a significant fraction of patients (20-30%) do not respond to the induction treatment and, among those achieving complete remission, relapse rates are high (∼40% of 5-year survival of in patients below 60 and ∼20% in older ones (Estey, 2012) ).
As it is the case for most cancers, no rapidly implementable prognosis tool is currently available at diagnosis to predict the response of AML to standard chemotherapy. This is detrimental for at least two reasons: (i) unnecessary exposure of chemoresistant patients to severe side-effects-generating genotoxics (Minotti et al, 2004) and (ii) loss of time before redirecting refractory patients to novel therapies (targeted therapies, immunotherapies…) and/or enrolling them in clinical trials for innovative therapeutic strategies. Transcriptomic signatures are now used to better stratify patients and adapt treatments in several cancers.
However, even though various transcriptomic signatures have been defined for AML, none of them is sufficiently reliable to be used in clinical practice. Proteomic signatures, in particular those based on mass spectrometry, are emerging as promising alternatives (Panis et al, 2016) .
Even closer to the biological functions dysregulated in cancer, « modifomic or PTMomic » analyses, which monitor the activity of enzymes involved in the post-translational modifications (PTM) of proteins, open new perspectives in cancer prognosis and diagnosis (Thygesen et al, 2018) .
Alterations in UbL modification being frequently found in AML, we have used AML as a model to address whether global analysis of UbL conjugation could define a new class modifomic biomarkers of patients' response to chemotherapeutic treatments. Using a largescale protein array-based screening, we identified a UbL signature of AML chemoresistance composed of 122 proteins. We then defined a score based on selected proteins allowing to predict the response to chemotherapy of both AML cell lines and AML patient cells. Finally, we developed a miniaturized assay implementable in clinical routine to rapidly quantify these new biomarkers.
Results
Analysis of UbL-conjugating activities using Protein Arrays.
To identify potential UbL-modified biomarker proteins, we resorted to protein arrays (Protoarrays, Life Technologies). They display >9000 recombinant human proteins spotted in duplicate on a nitrocellulose-coated slide. Such arrays have already been used successfully to identify substrates of certain E3 Ubiquitin ligases using either total cell extracts (Merbl & Kirschner, 2009) or recombinant enzymes (Gupta et al, 2007; del Rincón et al, 2010) . The arrays were incubated with cell extracts either from chemosensitive HL-60 or U937 reference AML cell lines, or from Ara-C-(ARA-R) or DNR-resistant (DNR-R) sublines that we generated from them ( Figure 1A ). As expected, the chemoresistant sublines showed significantly higher IC 50 for Ara-C and DNR ( Figure 1B substrates and quantification of their modifications were achieved by array scanning after incubation with, first, antibodies directed to either SUMO-1 or the Flag-tag epitope present on exogenous Ubiquitin and, then, fluorescent secondary antibodies ( Figure 1A ). Three independent experiments were performed for all cell lines (24 arrays in total). Signals were corrected for background, normalized using the PAA package (Turewicz et al, 2016) and analyzed using both the Welch and the Wilcoxon-Mann-Whitney statistical tests (see Methods for details). This led to the identification of 988 ubiquitylated-and 83 SUMOylated proteins, 72 proteins being both ubiquitylated and SUMOylated ( Figure 1C and Supplementary Table 1 ).
Identification of a UbL signature of AML resistance to standard chemotherapy.
Among the proteins identified as robustly ubiquitylated or SUMOylated on the arrays, we then selected those that were differentially modified between cell extracts from chemoresistant and parental cell lines. A first analysis was performed by comparing the pooled data obtained for all resistant cell lines to those from all sensitive ones. This led to the identification of 52 proteins differentially modified by Ubiquitin and 27 proteins differentially modified by SUMO-1 (Figure 2A and Supplementary Table 2 ), 4 of them being differentially modified by both UbLs. To identify biomarkers that might be specific for specific AML subtypes or for the resistance to one of the two drugs, we also performed a second analysis in which the data for each cell line (HL-60 and U937) and each resistance (DNR and Ara-C)
were considered separately. Although the sample size for each condition was smaller than in the first analysis, -and consequently the statistical significances lower-, we identified 65 proteins for Ubiquitin and 12 for SUMO-1 that were differentially modified in at least one of the resistant cell lines as compared to its parental counterpart ( Figure 2B and Supplementary Table 4 ).
An ontology analysis showed that these are principally involved in the Ubiquitin-Proteasome pathway, stress response, DNA damage repair and autophagy, which are all processes often dysregulated in chemoresistant cancer cells ( Figure 2C ).
Generation of a UbL score to predict patients' response to chemotherapeutic drugs.
To further validate the signature, in particular on patient samples, we selected 23 of the 122 proteins that showed both a high level of modification and the most robust signal differences between sensitive and resistant cell lines in the global or separated analysis ( Supplementary   Table 4 ). In a first step, we used them to generate a UbL score aiming at predicting patients' response to chemotherapy. To this aim, we applied a Genetic Algorithm (GA) (Scrucca, 2013) to select groups of proteins pertinent for predicting chemotherapy resistance in cell lines and in patients. We used 30 variables corresponding to the 23 selected proteins (7 SUMOylated + 9 ubiquitylated + 2x7 SUMOylated and ubiquitylated) (see Methods). The GA was run on the cell lines datasets multiple times with different parameter settings to obtain a total of 40 solutions (combinations of selected proteins). Out of the 30 variables, 25 were selected at least once in the 40 solutions obtained. They were ranked by their frequency of selection ( Figure 3A ), as frequently selected proteins are more likely to be predictive. We then divided this list in 5 embedded subsets containing an increasing number of selected variables/proteins ( Figure 3A) for Linear Discriminant Analysis (LDA), which uses an optimized linear combination of all variables to assign observations to target classes (here sensitive or resistant). As expected, we observed that the most frequently selected proteins were present in the most predictive selected solutions, which suggested that they were not random artefacts due to the genetic algorithm.
To validate the approach, we first used the LDA on cell lines with all the subsets and found that the solution containing the top7 proteins in the GA (subset 2) was the most efficient and could predict whether the cell line was sensitive or resistant to DNR or Ara-C in 16 cases out of 18 tested (6 cell lines, 3 replicates) ( Figure 3B ). To determine if it could also be used to predict AML patients' response to these drugs, we resorted to bone marrow aspirates from 4 patients, all of the rather immature M1 subtype in the FAB classification. Two of these patients were sensitive to induction chemotherapy (anthracycline + cytarabine) and two were refractory ( Supplementary Table 5 ). These samples were used to prepare extracts and probe Protoarrays as described above for cell lines. Interestingly, the LDA containing "subset 2"
proteins could predict the response to chemotherapy of all the 4 patients tested ( Figure 3C ).
Although a higher number of patient samples still need to be tested for stronger validation of the approach, our data suggest that the modifomic biomarkers we identified might be used to predict AML patients' response to chemotherapies.
Development of a miniaturized assay to measure signature protein modification by UbLs.
Protoarrays are useful to identify modifomic signatures. However, they are difficult to implement for routine clinical diagnosis due to the number of cells required, the challenge of their standardization and their high cost. To circumvent these difficulties, we developed a miniaturized flow cytometry assay to further evaluate the prognosis value of the biomarkers we identified. This assay is based on the use of Luminex XMap beads, which are color-coded magnetic beads. To validate it, we cloned the 23 selected proteins as fusion with glutathione-S-transferase (GST). Ten of them could be produced in E. coli and were coupled to differently colored XMap beads. The coupled beads were then multiplexed and incubated with cell extracts. They were then analyzed by flow cytometry using first anti-SUMO-1 or -Flag tag antibodies to quantify modification by SUMO-1 and Ubiquitin, respectively, and, then, specific secondary antibodies linked to two different fluorochromes ( Figure 4A ). If ubiquitylation was detected on most proteins tested, this was however not the case for SUMOylation. A most likely explanation for this discrepancy is that Ubiquitin can make long polyUbiquitin chains, facilitating their detection on protein substrates, whereas SUMO cannot. We consequently focused the rest of our study on ubiquitylated proteins. Out of the ten proteins tested, three proteins (UBADC1, STAM and SQSTM1) showed significant differences in their ubiquitylation levels between parental, Ara-C-and/or DNR-resistant U937
( Figure 4B and 4C). Interestingly, although all proteins were incubated simultaneously in the same extracts, differences could be detected in their modification. For example, the highest ubiquitylation of STAM was obtained using Ara-C resistant extracts whilst UBADC1 showed increased modification only with DNR resistant extracts. Altogether, these data suggest that bead-based detection of ubiquitylation provides an easy and quantitative way to detect specific alterations in the ubiquitylation cascade and identify STAM, UBADC1 and SQSTM1
as potential Ub-modifiable biomarkers of AML chemoresistance.
Analysis of UbL signature proteins in primary AML cells using the miniaturized flow cytometry assay.
To further validate the use of the beads-based assay, we used cell extracts prepared from bone marrow aspirates from 17 patients who responded, or not, to induction chemotherapy.
Interestingly, STAM, UBADC1 and SQSTM1 proteins showed a high level of ubiquitylation in 3/5 patients who did not respond to induction chemotherapy but only in 2/12 patients who responded ( Figure 5 and Supplementary Table 5 ). Surprizingly, one of the patients (#16185), who responded to the induction chemotherapy, showed very high levels of ubiquitylation of all 3 proteins. Interestingly, this patient had a complex karyotype, which is a marker of bad prognosis. This patient relapsed rapidly after initial chemotherapy. Altogether, this suggested that the ubiquitylation signature proteins, among them STAM, UBADC1 and SQSTM1, might serve as a therapeutic response biomarker in AMLs.
Discussion
In summary, our work points to a new class of biomarkers based on ubiquitin and SUMO conjugation that might be used to predict the response of AML patients to standard chemotherapies. In addition, we have developed a miniaturized assay that allows the quantification of these biomarkers using low amounts of cells and amenable to the use of patient samples.
Dysregulations of the Ubiquitin and SUMO conjugated proteome in cancer cells can be linked
to increased/decreased expression of their respective E1/E2/E3 conjugating enzymes, which could be (partly) monitored using transcriptomic approaches. However, in most cases, they are due to changes in their activities, which is more challenging to monitor, in particular in patient samples. Mass spectrometry has been widely used to analyze, at the proteome scale, cell protein SUMOylome and Ubiquitylome (Heap et al, 2017; Hendriks & Vertegaal, 2016) .
However, although the sensitivity of this technology increases rapidly, it still requires large amounts of material, which is generally not compatible with the use of patient samples as starting material. Moreover, the biological lability of the isopeptide bond linking UbLs to their substrates renders their mass-spectrometry identification particularly challenging. We used here protein arrays to monitor variations in the activity of UbL conjugating enzymes.
The protein array technology is endowed with several advantages. Firstly, as it relies on enzymatic activities, it is amenable to relatively small numbers of cells as compared to mass spectrometry approaches. Secondly, it does not rely on the abundance of the spotted proteins since they are present in similar amounts on the arrays. Finally, it allows the analysis of two different UbLs in the same sample/experiment. We focused our study on ubiquitin and SUMO conjugation, as these modifiers are the best-characterized and best-studied UbLs. We they are resistant to and/or to the AML subtype. We then generated scores based on the most robust proteins of the signature in terms of level and differences of UbL modification between the parental and the resistant AML cell lines we used as models. These scores were used on protein array data obtained with 4 patient's samples and one of the scores could retrospectively predict the response of these 4 patients to the chemotherapy. Even if the number of patients' samples was too small to validate this assay on a definitive statistical basis, our work nevertheless provides a proof of concept that such an approach could be used to help predict AML patients' response to current standard chemotherapies.
To further validate the modifomic biomarkers we identified, in particular in patients' samples, it was important to develop a miniaturized assay that would require less cells and be easily and rapidly (few hours) implementable for future use in clinical practice. The assay is based on the Luminex technology, which uses multiplexable color-coded microbeads. This technology is routinely used, including in clinical analysis services, to detect circulating hormones, chemokines, cytokines or auto-antigens using beads coupled with antibodies specific for these proteins. Here, instead of antibodies, we coupled purified recombinant proteins from the UbL-signature to the beads. The modified beads (one protein per bead color) were then multiplexed and incubated with cellular extracts, which were prepared under conditions preserving UbL-conjugating enzymes activities. This assay could precisely quantify the level of coupled protein modification by Ubiquitin and, thereby, precisely estimate the differences in their modification levels between samples. Among the proteins that we analyzed, we identified 3 proteins, STAM, UBADC1 and SQSTM1, which are differentially ubiquitylated with extracts from cell lines or patients that were resistant to chemotherapies compared to cells that are sensitive. It should however be noted that not all proteins identified on the Protoarrays could be validated in the XMap bead-based assay. At this stage of investigations, we do not exclude that this might be due to differences in their conformation and/or differences in pre-existing post-translational modifications, as they were produced in insect cells in the former case and in bacteria in the latter one. Along the same line, improvement of protein production and detection methods could also allow to better detect SUMOylation of the proteins we identified using the protein arrays and improve the prognosis efficiency of the assay.
AML is a therapeutic emergency, as patients most often need to start chemotherapy in the next few days after diagnosis. It is however critical to rapidly determine the risk/benefit ratio before starting current standard chemotherapy to which severe side-effects are associated.
Decision between intensive standard chemotherapy, epigenetic therapies (e.g. azacitidine) and
best-supportive care is currently mostly based on the age, fitness, co-morbidities of the patient. Cytogenetics, in particular the number of genetic abnormalities, can also be used as a prognosis marker. However, it generally takes one or two weeks for the clinicians to get the results. Most of the time, the treatment needs to be started before having these results. We have established the basis of an assay, based on UbL modifications by patients' cell extracts, that could be performed at diagnosis in few hours together with flow-cytometry analyses routinely carried out to confirm AML diagnosis. Its results, combined with the abovementioned criteria, might therefore help clinicians to propose the best therapeutic option to each patient, including redirection towards novel treatments or ongoing clinical trials, notably for emerging drugs targeting Ubiquitin or SUMO pathways.
Methods

Cell culture
HL-60 and U937 cells (DSMZ, Germany) were cultured at 37°C in RPMI medium supplemented with 10 % fetal bovine serum (FBS) and streptomycin/penicillin in the presence of 5 % CO 2 . Both cell lines were authenticated by the ATCC using Short-Tandem-Repeat analysis. All cells were regularly tested negative for mycoplasma. After thawing, cells were passaged at a density of 3x10 5 /ml every 2-3 days for no more than 10 passages. U937 and HL-60 cells resistant to Ara-C (cytarabine) and DNR were generated by culture in the presence of increasing drug concentrations (up to 0.1 µM for Ara-C and 0.03 µM for DNR) for 2-3 months.
Patient samples
Bone marrow aspirates were collected after obtaining written informed consent from patients under the frame of the declaration of Helsinki and after approval by the institutional "Sud Supplementary Table 5 .
IC 50 measurement
Cells were seeded at a concentration of 3x10 5 /mL in RPMI medium complemented with 0.1, 1, 10, 50, 100 or 250 µM of Ara-C (Sigma-Aldrich) or 0.01, 0.05, 0.1, 0.5, 1 or 10 µM of daunorubicin (Sigma-Aldrich). Viability was measured 24 hrs later using the MTS assay from Promega following the manufacturer's protocol. IC 50 were calculated using the GraphPad PRISM software.
Cellular extracts
Cell lines grown at a 5-8x10 5 /mL density or patient's bone marrow aspirates were spun down (300 g) at 4 °C for 5 min and washed once with PBS. After pellet resuspension in 1 mL of PBS, they were centrifuged again (16,000 g) at 4 °C for 5 min. Pellets were resuspended and incubated at 4 °C for 30 min in a hypotonic buffer (HEPES pH 7.5 20 mM, MgCl 2 1.5 mM, KCl 5 mM, DTT 1 mM and 1 mg/L of aprotinine, leupeptin and pepstatin) in a volume of either (i) 100 µL per 50x10 6 cells to generate concentrated extracts used for ProtoArray probing or (ii) 25 µL per 2x10 6 cells in the case of extracts used in XMap bead-based flow cytometry assays. Cell lysis was achieved through 4 freezing/thawing cycles using liquid nitrogen and DNA was sheared owing to 10 passages through a 20-1/2G needle. Extracts were finally centrifuged twice (16,000 g) at 4°C for 20 min and supernatants were aliquoted, flash-frozen and kept at -80 °C until use.
Protein arrays
Human Arrays were washed 5 times for 5 min with the washing buffer, once with H 2 O and, finally, dried by centrifugation before fluorescence scanning using the Innoscan 710 device from Innopsys.
Analysis of Protoarray data
Measured fluorescence intensities were associated to the corresponding protein ID according to their coordinates on the arrays using the Mapix software (Innopsys). Intensities were processed using the PAA R package (Turewicz et al, 2016) . In brief, (i) duplicated protein spot intensities were averaged using the LoadGPR function and (ii) the background was corrected using the BackgroundCorrect function. Fluorescence intensities within the same experiment were normalized by quantiles using the NormalizeArray function. Finally, intensities were normalized between the different experiments using the BatchAdjust function.
Data filtering
To identify the proteins modified by Ubiquitin or SUMO-1 on the ProtoArrays, we first had to filter proteins displaying signal significantly higher in UbL conjugation-permissive-conditions comparatively to non-permissive ones (i.e. control conditions using NEM-treated extracts ).
The classical Student t-test was not adapted to exploit our results, as variances could be very different between UbLs conjugation-permissive and non-permissive conditions. We therefore selected proteins with significant p-values (lower than 0.05) in both the parametrical Welchand the non-parametrical Wilcoxon-Mann-Whitney (WMW) tests. Then, proteins having an averaged normalized fluorescence intensity value less than 800 (arbitrary threshold) were filtered out in order to obtain a list of robustly modified proteins.
Identification of differentially UbL-modified proteins between chemosensitive and chemoresistant cells
The signal intensity ratios between the parental and the drug resistant cells for the proteins 
Ontology analysis
Ontology analyses were performed using the Panther software.
Genetic Algorithm and Linear Discriminant Analysis
The R package GA, providing a genetic algorithm (GA) (Scrucca, 2013) , was used. The aim was to determine the right number of variables in order to create a parsimonious predictive model. GAs are mathematical models inspired by Charles Darwin's model of natural selection. The natural selection preserves only the fittest individuals over the different
generations. An evolutionary algorithm improves the selection over time and allows the best solution to emerge from the best of prior solutions. The selected features were then tested with linear discriminant analysis (LDA) using the R package MASS (Venables & Ripley, 2002; Ripley, 1996) . This mathematical method uses a linear combination of all variables to assign observations to target classes. To this aim, it creates a decision rule based on the n available variables (score = * 1 + β * 2 + …. + * ) by maximizing the between-class variability and minimizing the within-class one. A cross-validation step that separates the observations in two groups (training dataset on which the model is established and test dataset on which the model is validated) was performed to get more robust results.
Production of recombinant proteins
cDNAs encoding the proteins of interest were recovered from the Ultimate ORF library (Thermofisher) and cloned in the bacterial expression vector pGGWA (Busso et al, 2005) vector using the Gateway technology according to the manufacturer's protocol (Life Technologies). Constructs were then transformed in the BL21 (DE3) E. coli strain. Protein production was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 6 hrs in bacteria exponentially growing at 25°C. Bacterial pellets were resuspended in Tris-HCl pH 8.6 50 mM containing NaCl 500 mM and MgSO 4 50 mM and flash-frozen in liquid N 2 . After thawing, bacterial suspensions were supplemented with 1 mg/mL lysozyme (Sigma-Aldrich), 8 mM -mercaptoethanol and 1 mg/L of aprotinin, leupeptin and pepstatin and incubated at 4°C for 1 hr. Bacterial debris were spun down at 100,000 g for 1 hr. The extract was then bound to glutathione agarose beads (Generon) equilibrated in buffer A (Tris-HCl pH 8.6 50 mM, NaCl 150 mM, MgSO 4 50 mM,-mercaptoethanol 8 mM and 1 µg/L of aprotinin, leupeptin and pepstatin). The column was then extensively washed with buffer A and eluted by addition of 20 mM reduced glutathione (Sigma-Aldrich).
Protein coupling to XMap 2x10 5 magnetic XMap beads (low concentration) from Luminex were transferred to a low binding microtube (Eppendorf) and washed using NaCl 500 mM. They were then resuspended in 50 µL of MES (2-ethanesulfonic acid) pH 6.1 50 mM and incubated in the presence of 5 µg/mL 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC, Pierce) and 5 µg/mL Sulfo-NHS (Pierce) at room temperature for 20 min under agitation.
Beads were then washed in PBS containing 500 mM NaCl and incubated with 7 µg of recombinant protein to be coupled in 100 µL PBS at room temperature for 2 hrs. They were then washed twice with PBS containing 0.1 % BSA, 0.02 % Tween 20, 0.05 % sodium azide and 500 mM NaCl and stored at 4 °C in PBS containing 0.1 % BSA, 0.02 % Tween-20, 0.05 % sodium azide.
UbLs conjugation to proteins coupled to XMap beads
SUMO-1-, SUMO-2-and Ubiquitin-vinyl sulfones (0.5 µM each) were added to diluted cellular extracts (10 µL), which were incubated at 4 °C for 15 min. Control extracts were also incubated with 100 mM NEM. We then added to the extract 10 Results were analysed using the FlowJow software. 
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